Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 9/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30011424 | 1.00 | ABL1 (0.48) | ABL1MAPK10BRD4SLC22A12PTGS1 | |
| SCHEMBL14599975 | 0.84 | BRD4 (0.43) | MAPK10BRD4SLC22A12 | |
| SCHEMBL31011117 | 0.81 | KDM4E (0.50) | MAPK10BRD4SLC22A12 | |
| SCHEMBL12508238 | 0.78 | KDM4E (0.58) | PIK3CG | |
| SCHEMBL31011093 | 0.78 | KDM4E (0.57) | ABL1BRD4SLC22A12 | |
| SCHEMBL1973088 | 0.77 | DEGS1 (0.46) | PIK3CG | |
| SCHEMBL7351894 | 0.77 | CA12 (0.46) | PTGS1PIK3CG | |
| SCHEMBL12018120 | 0.77 | KDM4E (0.60) | — | |
| SCHEMBL12266080 | 0.77 | ALDH1A1 (0.54) | BRD4SLC22A12PTGS1PTGS2 | |
| SCHEMBL12094975 | 0.77 | PIK3CG (0.41) | ABL1AURKACDK1CCNB1PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113490668-B | Compounds and compositions for the treatment of diseases associated with APJ receptor activity | 安娜普尔纳生物股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20240269137-A1 | HDAC6 INHIBITORS FOR TREATMENT OF DILATED CARDIOMYOPATHY | TENAYA THERAPEUTICS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | MEDSHINE DISCOVERY INC. (CN) | 2023-11-02 | — | — | US | disclosed |
| CN-113490668-A | Compounds and compositions for treating diseases associated with APJ receptor activity | 安娜普尔纳生物股份有限公司 | 2021-10-08 | — | — | CN | disclosed |
| WO-2021047674-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | 南京明德新药研发有限公司 | 2021-03-18 | — | — | WO | disclosed |
| US-8530486-B2 | Quinazolines and related heterocyclic compounds, and their therapeutic use | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2013-09-10 | — | — | US | disclosed |
| US-8530486-B2 | Quinazolines and related heterocyclic compounds, and their therapeutic use | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2013-09-10 | — | — | US | disclosed |
| US-8263585-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-8263585-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| EP-2173722-B1 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2012-08-29 | — | — | EP | disclosed |
| US-20100298322-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | VERENIGING VOOR CHRISTELIJK, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2010-11-25 | — | — | US | disclosed |
| WO-2009083608-A1 | QUINAZOLINES AND RELATED HETEROCYCLIC COMPOUNDS, AND THEIR THERAPEUTIC USE | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163463-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
| US-20090163463-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
| WO-2009013348-A2 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298322-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | RXFP3, RXFP1, NR1I3 | ABL1 135/4885MAPK10 2701/4885BRD4 453/4885 |
| US-20240269137-A1 | HDAC6 INHIBITORS FOR TREATMENT OF DILATED CARDIOMYOPATHY | HDAC6, HDAC1, HDAC2 | ABL1 4666/4885MAPK10 1644/4885BRD4 303/4885 |
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | CRBN, CRKL, NCOR1 | ABL1 1711/4885MAPK10 439/4885BRD4 1150/4885 |
| US-20090163463-A1 | Organic Compounds | PIK3C3, PIK3CA, MTOR | ABL1 238/4885MAPK10 83/4885BRD4 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.